Teva’s $40bn generic-drug buy sees Latham & Watkins and Sullivan & Cromwell lead

Cross-border teams from Sullivan & Cromwell and Latham & Watkins have landed the lead roles on the $40bn takeover of Allergan’s generic-making business by Teva that has seen the Israeli pharmaceutical powerhouse also abandon its bid for Mylan.

This article is for Legal Business subscribers. Please log in or subscribe to read on.

Related Content

Latham launches $1m AI awards programme for associates

‘These are significant items on clients’ balance sheets’ – inside Latham’s five-partner Houston projects play

Latham hires five Weil trainees in London as wind-down looms

Cravath makes rare London partner promotion amid 11-strong round

Sidley in talks to take Weil Paris office alongside heavyweight PE partners in London and Germany

Slaughters leads for Anthropic on UK share offer in IPO

Revolving doors: Simpson Thacher, Latham, Sidley lead New Year London moves

Five partners vie to succeed Hoyland as Simmons managing partner

‘Seize every opportunity’ – Paul Hastings partner Reena Gogna on City law, Suits and poetry